SHR-A1811 plus radiation for HER2 breast cancer brain mets
Part of Cancer, Skin clinical trials.
This trial tests a new drug (SHR-A1811) combined with radiation therapy for people with HER2-positive or HER2-low breast cancer that has spread to the brain. It aims to see if the combination can better control brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive (IHC 3+ or IHC 2+/FISH+) or HER2-low (IHC 1+ or 2+/FISH-) advanced breast cancer
- You are 18 years or older
- You have newly diagnosed brain metastases (fewer than 6 spots) confirmed by MRI
- You have had no more than 4 previous treatments for advanced breast cancer
- You are expected to live at least 3 more months
- You do not have a history of taking the drug T-DXd
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
This study tests a new drug, SHR-A1811, for women with HER2-positive breast cancer that has spread to the brain. The trial will see if the drug can shrink tumors in the brain and body.
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
This trial tests two new drugs, SHR-A1811 and THPy, in people with HER2 positive advanced breast cancer that has spread to the brain. It is for those who have not received any previous treatment for advanced cancer.
This trial tests a combination of two drugs (SHR-A1921 and Avastin) to see if it can shrink or slow brain tumors caused by triple-negative breast cancer. It’s for people whose breast cancer has spread to the brain and haven’t had radiation to the brain yet.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.